454 Checkpoint modification of early T cell activation provides enhanced anti-tumor activity and survival benefits in a fast-growing preclinical tumor challenge model

• Sue L Currie,
• Mohsen Mohammadi,
• Xiang Y Zhou,
• Zhi Xiang,
• Wynetta Giles-Davis,
• Andrew Luber,
• Hildegund CJ Ertl

Affiliations

Sue L Currie

Nektar Therapeutics, San Francisco, California, USA

Mohsen Mohammadi

1The Wistar Institute, Philadelphia, PA, USA

Xiang Y Zhou

1The Wistar Institute, Philadelphia, PA, USA

Zhi Xiang

1The Wistar Institute, Philadelphia, PA, USA

Wynetta Giles-Davis

1The Wistar Institute, Philadelphia, PA, USA

Andrew Luber

2Virion Therapeutics, Newark, DE, USA

Hildegund CJ Ertl

1The Wistar Institute, Philadelphia, PA, USA